CART-19 Cells for R/R B-cell Lymphoma (CCFRRBL)

Fujian Medical University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Relapsed or Refractory B-cell Lymphoma

Treatments: Other: CART-19 cells

Study type: Interventional

Funder types: Other

Identifiers

NCT03391726

CART-19-01

Details and patient eligibility

About

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

Enrollment: 20 estimated patients

Sex: All

Ages: 1 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent
• Aged between 1-65 years
• Patients with relapse/refractory B-cell lymphoma
• Cardiac: Left ventricular ejection fraction ≥ 50%
• Adequate renal and hepatic function
• Performance status: Karnofsky ≥ 70%

Exclusion criteria

• Pregnant or lactating females.
• Any co-morbidity precluding the administration of CART-19 cells.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Arm 1

Experimental group

Description:

CART-19 cells treat

Treatment:

Other: CART-19 cells